THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING
A trial fibrillation occurs in 5 to 8% of patients who underwent percutaneous coronary intervention (PCI) with stenting. It is known that dual antiplatelet therapy (a combination of P2Y12 receptor inhibitor and acetylsalicylic acid) significantly reduces the risk of developing stent thrombosis in co...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
«REMEDIUM GROUP» Ltd.,
2017-05-01T00:00:00Z.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sailkapena: |
A1234.567 |
|---|---|
| Alea 1 | Eskuragarri |